Literature DB >> 15990866

p53 gene mutations are uncommon but p53 is commonly expressed in anaplastic large-cell lymphoma.

G Z Rassidakis1, A Thomaides, S Wang, Y Jiang, A Fourtouna, R Lai, L J Medeiros.   

Abstract

Anaplastic large-cell lymphoma (ALCL), as defined in the World Health Organization, is a heterogeneous category in which a subset of cases is associated with the t(2;5)(p23;q35) or variant translocations resulting in overexpression of anaplastic lymphoma kinase (ALK). p53 has not been assessed in currently defined subsets of ALCL tumors. In this study, we assessed ALK+ and ALK- ALCL tumors for p53 gene alterations using PCR, single-strand conformation polymorphism and direct sequencing methods. We also immunohistochemically assessed ALCL tumors for p53 expression. Three of 36 (8%) ALCL tumors (1/14 ALK+, 2/22 ALK-) with adequate DNA showed p53 gene mutations. By contrast, p53 was overexpressed in 36 of 55 (65%) ALCL tumors (16 ALK+, 20 ALK-). p21, a target of p53, was expressed in 15 of 31 (48%) ALCL tumors including seven of 15 (47%) p53-positive tumors. p21 expression in a subset of ALCL suggests the presence of functional p53 protein. Apoptotic rate was significantly higher in p53-positive than p53-negative tumors (mean 2.78 vs 0.91%, P = 0.0003). We conclude that the p53 gene is rarely mutated in ALK+ and ALK- ALCL tumors. Nevertheless, wild-type p53 gene product is commonly overexpressed in ALCL and may be functional in a subset of these tumors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15990866     DOI: 10.1038/sj.leu.2403840

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  15 in total

1.  Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma.

Authors:  Tammy Linlin Song; Maarja-Liisa Nairismägi; Yurike Laurensia; Jing-Quan Lim; Jing Tan; Zhi-Mei Li; Wan-Lu Pang; Atish Kizhakeyil; Giovani-Claresta Wijaya; Da-Chuan Huang; Sanjanaa Nagarajan; Burton Kuan-Hui Chia; Daryl Cheah; Yan-Hui Liu; Fen Zhang; Hui-Lan Rao; Tiffany Tang; Esther Kam-Yin Wong; Jin-Xin Bei; Jabed Iqbal; Nicholas-Francis Grigoropoulos; Siok-Bian Ng; Wee-Joo Chng; Bin-Tean Teh; Soo-Yong Tan; Navin Kumar Verma; Hao Fan; Soon-Thye Lim; Choon-Kiat Ong
Journal:  Blood       Date:  2018-07-27       Impact factor: 22.113

2.  MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.

Authors:  Zijun Y Xu-Monette; Michael B Møller; Alexander Tzankov; Santiago Montes-Moreno; Wenwei Hu; Ganiraju C Manyam; Louise Kristensen; Lei Fan; Carlo Visco; Karen Dybkaer; April Chiu; Wayne Tam; Youli Zu; Govind Bhagat; Kristy L Richards; Eric D Hsi; William W L Choi; J Han van Krieken; Qin Huang; Jooryung Huh; Weiyun Ai; Maurilio Ponzoni; Andrés J M Ferreri; Lin Wu; Xiaoying Zhao; Carlos E Bueso-Ramos; Sa A Wang; Ronald S Go; Yong Li; Jane N Winter; Miguel A Piris; L Jeffrey Medeiros; Ken H Young
Journal:  Blood       Date:  2013-08-27       Impact factor: 22.113

3.  Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas.

Authors:  George Vasmatzis; Sarah H Johnson; Ryan A Knudson; Rhett P Ketterling; Esteban Braggio; Rafael Fonseca; David S Viswanatha; Mark E Law; N Sertac Kip; Nazan Ozsan; Stefan K Grebe; Lori A Frederick; Bruce W Eckloff; E Aubrey Thompson; Marshall E Kadin; Dragana Milosevic; Julie C Porcher; Yan W Asmann; David I Smith; Irina V Kovtun; Stephen M Ansell; Ahmet Dogan; Andrew L Feldman
Journal:  Blood       Date:  2012-08-01       Impact factor: 22.113

4.  Aberrant anaplastic lymphoma kinase activity induces a p53 and Rb-dependent senescence-like arrest in the absence of detectable p53 stabilization.

Authors:  Fiona Kate Elizabeth McDuff; Suzanne Dawn Turner
Journal:  PLoS One       Date:  2011-03-14       Impact factor: 3.240

Review 5.  The Role of Oncogenic Tyrosine Kinase NPM-ALK in Genomic Instability.

Authors:  Cosimo Lobello; Vasilis Bikos; Andrea Janikova; Sarka Pospisilova
Journal:  Cancers (Basel)       Date:  2018-03-05       Impact factor: 6.639

Review 6.  Treating hematological malignancies with drugs inhibiting ribosome biogenesis: when and why.

Authors:  Enrico Derenzini; Alessandra Rossi; Davide Treré
Journal:  J Hematol Oncol       Date:  2018-05-31       Impact factor: 17.388

7.  Frequent activating STAT3 mutations and novel recurrent genomic abnormalities detected in breast implant-associated anaplastic large cell lymphoma.

Authors:  Piers Blombery; Ella Thompson; Georgina L Ryland; Rachel Joyce; David J Byrne; Christine Khoo; Stephen Lade; Mark Hertzberg; Greg Hapgood; Paula Marlton; Anand Deva; Geoffrey Lindeman; Stephen Fox; David Westerman; Miles Prince
Journal:  Oncotarget       Date:  2018-11-16

8.  Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency.

Authors:  Monica Ceccon; Maria Elena Boggio Merlo; Luca Mologni; Teresa Poggio; Lydia M Varesio; Matteo Menotti; Silvia Bombelli; Roberta Rigolio; Andrea D Manazza; Filomena Di Giacomo; Chiara Ambrogio; Giovanni Giudici; Cesare Casati; Cristina Mastini; Mara Compagno; Suzanne D Turner; Carlo Gambacorti-Passerini; Roberto Chiarle; Claudia Voena
Journal:  Oncogene       Date:  2015-12-14       Impact factor: 9.867

9.  Genetic landscape of T- and NK-cell post-transplant lymphoproliferative disorders.

Authors:  Elizabeth Margolskee; Vaidehi Jobanputra; Preti Jain; Jinli Chen; Karthik Ganapathi; Odelia Nahum; Brynn Levy; Julie Morscio; Vundavalli Murty; Thomas Tousseyn; Bachir Alobeid; Mahesh Mansukhani; Govind Bhagat
Journal:  Oncotarget       Date:  2016-06-21

10.  Breast implant-associated anaplastic large cell lymphoma in a Li-FRAUMENI patient: a case report.

Authors:  Ricardo Garcia Pastorello; Felipe D'Almeida Costa; Cynthia A B T Osório; Fabiana B A Makdissi; Stephania Martins Bezerra; Marina de Brot; Antonio Hugo J F M Campos; Fernando Augusto Soares; José Vassallo
Journal:  Diagn Pathol       Date:  2018-01-25       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.